2025 — Exosomal pHERV-W ENV as MS relapse-prediction biomarker
One-paragraph summary
Three-cohort study validating exosomal pHERV-W ENV (HERV-W envelope protein captured on serum-derived exosomes) as a dynamic biomarker in relapsing-remitting MS. Cohort 1: cross-sectional, healthy controls vs. stable MS vs. active disease. Cohort 2: longitudinal RRMS with samples before, during, and after disease activity. Result: exosomal pHERV-W ENV is enriched on serum exosomes in RRMS patients; levels reflect both current disease activity and future relapse risk. For the project, this is methodologically important — the biomarker-mapping cohort's HERV-W ENV dimension (#5, currently serum-protein per Oltra 2023 / Giménez-Orenga 2025 ELISA protocols) could be upgraded to exosomal capture for greater sensitivity and dynamic-range detection. Direct refinement to the 14-dimensional cohort design. Cross-condition methodology — pairs with the 2025 exosomal HERV-K MND paper for an extracellular-vesicle-anchored HERV biomarker measurement paradigm.
Claims as triples
HERV_W_ENV — present_in → multiple_sclerosis[evidence: cross-sectional + longitudinal exosomal biomarker validation; confidence: established]HERV_W_ENV — predicts → relapse_risk[evidence: longitudinal-cohort future-risk reflection; confidence: emerging]exosomal_biomarker — bridges → fm_central_only[evidence: cross-condition methodology applicable to HERV-W ENV measurement in FM biomarker cohort; confidence: bridging]
Triangulation notes
- Methodological upgrade for the project's biomarker-mapping cohort design. Dimension #5 should consider exosomal capture in addition to serum-protein measurement. Sensitivity and dynamic-range advantages support relapse-or-flare prediction in FM-HERV+ subset.
- Pairs with the 2025 exosomal HERV-K MND paper (also ingested this run) — together establish exosomal HERV protein capture as a cross-condition measurement methodology.
- Discovered via watchlist query WL-1 (temelimab MS Phase 2). Does not constitute Phase 2 efficacy readout; ingested as methodological-refinement contribution.